Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
6.53
-0.29 (-4.32%)
At close: Apr 28, 2026, 4:00 PM EDT
6.53
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Verrica Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 35.58 | 7.57 | 5.12 | 9.03 | 12 | |
| Revenue Growth (YoY) | 370.22% | 47.66% | -43.27% | -24.73% | - | |
| Cost of Revenue | 12.3 | 14.58 | 21.04 | 12.92 | 15.93 | |
| Gross Profit | 23.28 | -7.01 | -15.92 | -3.89 | -3.93 | |
| Selling, General & Admin | 35.22 | 58.82 | 47.31 | 17.41 | 26.98 | |
| Operating Expenses | 35.22 | 58.82 | 47.31 | 17.41 | 26.98 | |
| Operating Income | -11.94 | -65.84 | -63.22 | -21.3 | -30.91 | |
| Interest Expense | -7.74 | -9.41 | -3.96 | -2.17 | -4.3 | |
| Interest & Investment Income | 0.93 | 1.42 | 2.74 | 0.48 | 0.12 | |
| Other Non Operating Income (Expenses) | 2.65 | -2.67 | -0.01 | -0.06 | - | |
| EBT Excluding Unusual Items | -16.11 | -76.5 | -64.46 | -23.05 | -35.08 | |
| Gain (Loss) on Sale of Assets | -0.25 | -0.08 | -2.54 | - | - | |
| Other Unusual Items | -1.53 | - | - | -1.44 | - | |
| Pretax Income | -17.89 | -76.58 | -67 | -24.49 | -35.08 | |
| Earnings From Continuing Operations | -17.89 | -76.58 | -67 | -24.49 | -35.08 | |
| Net Income | -17.89 | -76.58 | -67 | -24.49 | -35.08 | |
| Net Income to Common | -17.89 | -76.58 | -67 | -24.49 | -35.08 | |
| Shares Outstanding (Basic) | 11 | 5 | 5 | 3 | 3 | |
| Shares Outstanding (Diluted) | 11 | 5 | 5 | 3 | 3 | |
| Shares Change (YoY) | 105.61% | 14.26% | 32.72% | 26.32% | 8.20% | |
| EPS (Basic) | -1.68 | -14.78 | -14.78 | -7.17 | -12.97 | |
| EPS (Diluted) | -1.68 | -14.78 | -14.78 | -7.17 | -13.00 | |
| Free Cash Flow | -17.63 | -60.95 | -38.94 | -18.95 | -28.47 | |
| Free Cash Flow Per Share | -1.66 | -11.77 | -8.59 | -5.55 | -10.53 | |
| Gross Margin | 65.44% | -92.70% | - | -43.08% | -32.74% | |
| Operating Margin | -33.56% | -870.16% | -1233.84% | -235.78% | -257.57% | |
| Profit Margin | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% | |
| Free Cash Flow Margin | -49.55% | -805.63% | -759.93% | -209.83% | -237.21% | |
| EBITDA | -11.45 | -64.88 | -62.67 | -20.84 | -30.66 | |
| EBITDA Margin | -32.20% | - | - | -230.76% | -255.53% | |
| D&A For EBITDA | 0.49 | 0.96 | 0.55 | 0.45 | 0.24 | |
| EBIT | -11.94 | -65.84 | -63.22 | -21.3 | -30.91 | |
| EBIT Margin | -33.56% | - | - | -235.78% | -257.57% | |
| Revenue as Reported | 35.58 | 7.57 | 5.12 | 9.03 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.